http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 08:35:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++InflaRx+N.V.+++++++++++++++++++++++++++Filed+by%3A+Sirenia+Capital+Management+LP/26925223.html si-local-file:///var/storage/secattach/20260814/26925223.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++InflaRx+N.V.+++++++++++++++++++++++++++Filed+by%3A+Sirenia+Capital+Management+LP/26925223.html Fri, 14 Aug 2026 08:35:00 -0400 IFRX O.32273423 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++InflaRx+N.V.+++++++++++++++++++++++++++Filed+by%3A+Sirenia+Capital+Management+LP/26925223.html si-local-file:///var/storage/secattach/20260814/26925223.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++InflaRx+N.V.+++++++++++++++++++++++++++Filed+by%3A+Sirenia+Capital+Management+LP/26925223.html Fri, 14 Aug 2026 08:35:00 -0400 IFRX O.32273423 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++InflaRx+N.V.+++++++++++++++++++++++++++Filed+by%3A+FARALLON+CAPITAL+MANAGEMENT%2C+L.L.C./26925029.html si-local-file:///var/storage/secattach/20260814/26925029.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++InflaRx+N.V.+++++++++++++++++++++++++++Filed+by%3A+FARALLON+CAPITAL+MANAGEMENT%2C+L.L.C./26925029.html Fri, 14 Aug 2026 08:22:00 -0400 IFRX O.32273423 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++InflaRx+N.V.+++++++++++++++++++++++++++Filed+by%3A+FARALLON+CAPITAL+MANAGEMENT%2C+L.L.C./26925029.html si-local-file:///var/storage/secattach/20260814/26925029.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++InflaRx+N.V.+++++++++++++++++++++++++++Filed+by%3A+FARALLON+CAPITAL+MANAGEMENT%2C+L.L.C./26925029.html Fri, 14 Aug 2026 08:22:00 -0400 IFRX O.32273423 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++InflaRx+N.V.+++++++++++++++++++++++++/26915746.html si-local-file:///var/storage/secattach/20260813/26915746.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++InflaRx+N.V.+++++++++++++++++++++++++/26915746.html Thu, 13 Aug 2026 06:06:00 -0400 IFRX O.32273423 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++InflaRx+N.V.+++++++++++++++++++++++++/26915746.html si-local-file:///var/storage/secattach/20260813/26915746.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++InflaRx+N.V.+++++++++++++++++++++++++/26915746.html Thu, 13 Aug 2026 06:06:00 -0400 IFRX O.32273423 http://www.streetinsider.com/Analyst+PT+Change/Inflarx+NV+%28IFRX%29+PT+Raised+to+%246+at+Cantor+Fitzgerald/26889313.html Cantor Fitzgerald analyst Steven Seedhouse raised the price target on Inflarx NV (NASDAQ: IFRX) to $6.00 (from $4.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Inflarx+NV+%28IFRX%29+PT+Raised+to+%246+at+Cantor+Fitzgerald/26889313.html Fri, 07 Aug 2026 11:09:31 -0400 IFRX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++InflaRx+N.V.+++++++++++++++++++++++++++Filed+by%3A+FMR+LLC/26881176.html si-local-file:///var/storage/secattach/20260806/26881176.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++InflaRx+N.V.+++++++++++++++++++++++++++Filed+by%3A+FMR+LLC/26881176.html Thu, 06 Aug 2026 10:29:00 -0400 IFRX O.32273423 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++InflaRx+N.V.+++++++++++++++++++++++++++Filed+by%3A+FMR+LLC/26881176.html si-local-file:///var/storage/secattach/20260806/26881176.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++InflaRx+N.V.+++++++++++++++++++++++++++Filed+by%3A+FMR+LLC/26881176.html Thu, 06 Aug 2026 10:29:00 -0400 IFRX O.32273423 http://www.streetinsider.com/SEC+Filings/Form++F-3++++++++InflaRx+N.V.+++++++++++++++++++++++++/26880616.html si-local-file:///var/storage/secattach/20260806/26880616.html http://www.streetinsider.com/SEC+Filings/Form++F-3++++++++InflaRx+N.V.+++++++++++++++++++++++++/26880616.html Thu, 06 Aug 2026 09:21:00 -0400 IFRX O.32273423 http://www.streetinsider.com/SEC+Filings/Form++F-3++++++++InflaRx+N.V.+++++++++++++++++++++++++/26880616.html si-local-file:///var/storage/secattach/20260806/26880616.html http://www.streetinsider.com/SEC+Filings/Form++F-3++++++++InflaRx+N.V.+++++++++++++++++++++++++/26880616.html Thu, 06 Aug 2026 09:21:00 -0400 IFRX O.32273423 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++InflaRx+N.V.+++++++++++++++++++++++++/26880605.html si-local-file:///var/storage/secattach/20260806/26880605.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++InflaRx+N.V.+++++++++++++++++++++++++/26880605.html Thu, 06 Aug 2026 09:19:00 -0400 IFRX O.32273423 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++InflaRx+N.V.+++++++++++++++++++++++++/26880605.html si-local-file:///var/storage/secattach/20260806/26880605.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++InflaRx+N.V.+++++++++++++++++++++++++/26880605.html Thu, 06 Aug 2026 09:19:00 -0400 IFRX O.32273423 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++InflaRx+N.V.++++++++++++++For%3A+Aug+06/26879040.html si-local-file:///var/storage/secattach/20260806/26879040.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++InflaRx+N.V.++++++++++++++For%3A+Aug+06/26879040.html Thu, 06 Aug 2026 07:56:00 -0400 IFRX O.32273423 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++InflaRx+N.V.++++++++++++++For%3A+Aug+06/26879040.html si-local-file:///var/storage/secattach/20260806/26879040.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++InflaRx+N.V.++++++++++++++For%3A+Aug+06/26879040.html Thu, 06 Aug 2026 07:56:00 -0400 IFRX O.32273423 http://www.streetinsider.com/Earnings/InflaRx+N.V.+%28IFRX%29+Misses+Q2+EPS+by+2c/26878876.html <p>InflaRx N.V. (NASDAQ: IFRX) reported Q2 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07).</p><p>For earnings history and earnings-related data on InflaRx N.V. (IFRX) <a href="http://www.streetinsider.com/ec_earnings.php?q=IFRX">click here</a>.</p> http://www.streetinsider.com/Earnings/InflaRx+N.V.+%28IFRX%29+Misses+Q2+EPS+by+2c/26878876.html Thu, 06 Aug 2026 07:33:34 -0400 IFRX http://www.streetinsider.com/Press+Releases/InflaRx+Reports+Second+Quarter+2026+Results+and+Highlights+Key+Achievements+and+Expected+Milestones/26878828.html <ul type="disc"><li style="text-align:left;">Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned</li><li style="text-align:left;">Initiated feasibility assessment for broadened strategy for AAV in Europe Reported new pre-clinical data supporting the safety and differentiation of izicopan as a next-generation oral inhibitor of C5aR</li><li style="text-align:left;">Pharmacokinetic (PK) bridging study in China expected to start late this year, with a goal to accelerate izicopan proof-of-concept studies in additional inflammation and immunology (I&amp;I) indications</li><li style="text-align:left;">Virtual Capital Markets Day planned for October 8, 2026 in the morning ET</li><li style="text-align:left;">Cash, cash equivalents and marketable securities totaled €158.4 million on June 30, 2026, http://www.streetinsider.com/Press+Releases/InflaRx+Reports+Second+Quarter+2026+Results+and+Highlights+Key+Achievements+and+Expected+Milestones/26878828.html Thu, 06 Aug 2026 07:30:00 -0400 A.06822034 A.50214048 IFRX O.00817244 O.20026344 O.32273423 http://www.streetinsider.com/Press+Releases/InflaRx+Reports+Second+Quarter+2026+Results+and+Highlights+Key+Achievements+and+Expected+Milestones/26878828.html <ul type="disc"><li style="text-align:left;">Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned</li><li style="text-align:left;">Initiated feasibility assessment for broadened strategy for AAV in Europe Reported new pre-clinical data supporting the safety and differentiation of izicopan as a next-generation oral inhibitor of C5aR</li><li style="text-align:left;">Pharmacokinetic (PK) bridging study in China expected to start late this year, with a goal to accelerate izicopan proof-of-concept studies in additional inflammation and immunology (I&amp;I) indications</li><li style="text-align:left;">Virtual Capital Markets Day planned for October 8, 2026 in the morning ET</li><li style="text-align:left;">Cash, cash equivalents and marketable securities totaled €158.4 million on June 30, 2026, http://www.streetinsider.com/Press+Releases/InflaRx+Reports+Second+Quarter+2026+Results+and+Highlights+Key+Achievements+and+Expected+Milestones/26878828.html Thu, 06 Aug 2026 07:30:00 -0400 A.06822034 A.50214048 IFRX O.00817244 O.20026344 O.32273423 http://www.streetinsider.com/Press+Releases/InflaRx+Reports+Second+Quarter+2026+Results+and+Highlights+Key+Achievements+and+Expected+Milestones/26878828.html <ul type="disc"><li style="text-align:left;">Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned</li><li style="text-align:left;">Initiated feasibility assessment for broadened strategy for AAV in Europe Reported new pre-clinical data supporting the safety and differentiation of izicopan as a next-generation oral inhibitor of C5aR</li><li style="text-align:left;">Pharmacokinetic (PK) bridging study in China expected to start late this year, with a goal to accelerate izicopan proof-of-concept studies in additional inflammation and immunology (I&amp;I) indications</li><li style="text-align:left;">Virtual Capital Markets Day planned for October 8, 2026 in the morning ET</li><li style="text-align:left;">Cash, cash equivalents and marketable securities totaled €158.4 million on June 30, 2026, http://www.streetinsider.com/Press+Releases/InflaRx+Reports+Second+Quarter+2026+Results+and+Highlights+Key+Achievements+and+Expected+Milestones/26878828.html Thu, 06 Aug 2026 07:30:00 -0400 A.06822034 A.50214048 IFRX O.00817244 O.20026344 O.32273423 http://www.streetinsider.com/Press+Releases/InflaRx+Reports+Second+Quarter+2026+Results+and+Highlights+Key+Achievements+and+Expected+Milestones/26878828.html <ul type="disc"><li style="text-align:left;">Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned</li><li style="text-align:left;">Initiated feasibility assessment for broadened strategy for AAV in Europe Reported new pre-clinical data supporting the safety and differentiation of izicopan as a next-generation oral inhibitor of C5aR</li><li style="text-align:left;">Pharmacokinetic (PK) bridging study in China expected to start late this year, with a goal to accelerate izicopan proof-of-concept studies in additional inflammation and immunology (I&amp;I) indications</li><li style="text-align:left;">Virtual Capital Markets Day planned for October 8, 2026 in the morning ET</li><li style="text-align:left;">Cash, cash equivalents and marketable securities totaled €158.4 million on June 30, 2026, http://www.streetinsider.com/Press+Releases/InflaRx+Reports+Second+Quarter+2026+Results+and+Highlights+Key+Achievements+and+Expected+Milestones/26878828.html Thu, 06 Aug 2026 07:30:00 -0400 A.06822034 A.50214048 IFRX O.00817244 O.20026344 O.32273423 http://www.streetinsider.com/Press+Releases/InflaRx+Reports+Second+Quarter+2026+Results+and+Highlights+Key+Achievements+and+Expected+Milestones/26878828.html <ul type="disc"><li style="text-align:left;">Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned</li><li style="text-align:left;">Initiated feasibility assessment for broadened strategy for AAV in Europe Reported new pre-clinical data supporting the safety and differentiation of izicopan as a next-generation oral inhibitor of C5aR</li><li style="text-align:left;">Pharmacokinetic (PK) bridging study in China expected to start late this year, with a goal to accelerate izicopan proof-of-concept studies in additional inflammation and immunology (I&amp;I) indications</li><li style="text-align:left;">Virtual Capital Markets Day planned for October 8, 2026 in the morning ET</li><li style="text-align:left;">Cash, cash equivalents and marketable securities totaled €158.4 million on June 30, 2026, http://www.streetinsider.com/Press+Releases/InflaRx+Reports+Second+Quarter+2026+Results+and+Highlights+Key+Achievements+and+Expected+Milestones/26878828.html Thu, 06 Aug 2026 07:30:00 -0400 A.06822034 A.50214048 IFRX O.00817244 O.20026344 O.32273423 http://www.streetinsider.com/Press+Releases/InflaRx+Reports+Second+Quarter+2026+Results+and+Highlights+Key+Achievements+and+Expected+Milestones/26878828.html <ul type="disc"><li style="text-align:left;">Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned</li><li style="text-align:left;">Initiated feasibility assessment for broadened strategy for AAV in Europe Reported new pre-clinical data supporting the safety and differentiation of izicopan as a next-generation oral inhibitor of C5aR</li><li style="text-align:left;">Pharmacokinetic (PK) bridging study in China expected to start late this year, with a goal to accelerate izicopan proof-of-concept studies in additional inflammation and immunology (I&amp;I) indications</li><li style="text-align:left;">Virtual Capital Markets Day planned for October 8, 2026 in the morning ET</li><li style="text-align:left;">Cash, cash equivalents and marketable securities totaled €158.4 million on June 30, 2026, http://www.streetinsider.com/Press+Releases/InflaRx+Reports+Second+Quarter+2026+Results+and+Highlights+Key+Achievements+and+Expected+Milestones/26878828.html Thu, 06 Aug 2026 07:30:00 -0400 A.06822034 A.50214048 IFRX O.00817244 O.20026344 O.32273423 http://www.streetinsider.com/Globe+Newswire/InflaRx+Reports+Second+Quarter+2026+Results+and+Highlights+Key+Achievements+and+Expected+Milestones/26878828.html <ul type="disc"><li style="text-align:left;">Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned</li><li style="text-align:left;">Initiated feasibility assessment for broadened strategy for AAV in Europe Reported new pre-clinical data supporting the safety and differentiation of izicopan as a next-generation oral inhibitor of C5aR</li><li style="text-align:left;">Pharmacokinetic (PK) bridging study in China expected to start late this year, with a goal to accelerate izicopan proof-of-concept studies in additional inflammation and immunology (I&amp;I) indications</li><li style="text-align:left;">Virtual Capital Markets Day planned for October 8, 2026 in the morning ET</li><li style="text-align:left;">Cash, cash equivalents and marketable securities totaled €158.4 million on June 30, 2026, http://www.streetinsider.com/Globe+Newswire/InflaRx+Reports+Second+Quarter+2026+Results+and+Highlights+Key+Achievements+and+Expected+Milestones/26878828.html Thu, 06 Aug 2026 07:30:00 -0400 A.06822034 A.50214048 IFRX O.00817244 O.20026344 O.32273423 http://www.streetinsider.com/Globe+Newswire/InflaRx+Reports+Second+Quarter+2026+Results+and+Highlights+Key+Achievements+and+Expected+Milestones/26878828.html <ul type="disc"><li style="text-align:left;">Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned</li><li style="text-align:left;">Initiated feasibility assessment for broadened strategy for AAV in Europe Reported new pre-clinical data supporting the safety and differentiation of izicopan as a next-generation oral inhibitor of C5aR</li><li style="text-align:left;">Pharmacokinetic (PK) bridging study in China expected to start late this year, with a goal to accelerate izicopan proof-of-concept studies in additional inflammation and immunology (I&amp;I) indications</li><li style="text-align:left;">Virtual Capital Markets Day planned for October 8, 2026 in the morning ET</li><li style="text-align:left;">Cash, cash equivalents and marketable securities totaled €158.4 million on June 30, 2026, http://www.streetinsider.com/Globe+Newswire/InflaRx+Reports+Second+Quarter+2026+Results+and+Highlights+Key+Achievements+and+Expected+Milestones/26878828.html Thu, 06 Aug 2026 07:30:00 -0400 A.06822034 A.50214048 IFRX O.00817244 O.20026344 O.32273423 http://www.streetinsider.com/Globe+Newswire/InflaRx+Reports+Second+Quarter+2026+Results+and+Highlights+Key+Achievements+and+Expected+Milestones/26878828.html <ul type="disc"><li style="text-align:left;">Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned</li><li style="text-align:left;">Initiated feasibility assessment for broadened strategy for AAV in Europe Reported new pre-clinical data supporting the safety and differentiation of izicopan as a next-generation oral inhibitor of C5aR</li><li style="text-align:left;">Pharmacokinetic (PK) bridging study in China expected to start late this year, with a goal to accelerate izicopan proof-of-concept studies in additional inflammation and immunology (I&amp;I) indications</li><li style="text-align:left;">Virtual Capital Markets Day planned for October 8, 2026 in the morning ET</li><li style="text-align:left;">Cash, cash equivalents and marketable securities totaled €158.4 million on June 30, 2026, http://www.streetinsider.com/Globe+Newswire/InflaRx+Reports+Second+Quarter+2026+Results+and+Highlights+Key+Achievements+and+Expected+Milestones/26878828.html Thu, 06 Aug 2026 07:30:00 -0400 A.06822034 A.50214048 IFRX O.00817244 O.20026344 O.32273423